Vivaldi Biosciences AG

Vivaldi Biosciences is developing genetically engineered intranasal vaccines for epidemic and pandemic viral respiratory diseases. Our lead vaccine candidates are:

• Delta-19: Combination Covid-19 + Universal Influenza Vaccine (preclinical)
• DeltaFLU: Universal Influenza Vaccine (Phase 2 clinical development)

We have developed a rapid, high-yield Vero-cell based manufacturing system and produced vaccines under GMP for clinical trials.

Our vaccine candidates are based on our Delta NS1 technology platform. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Intranasal administration of Delta NS1 vaccines generates a first line of defense by inducing interferon and broadly cross-neutralizing antibodies in the nasal mucosa, the point of entry of respiratory viral pathogens. The self-adjuvanting effect of interferon also creates a second line of defense, activating cytotoxic T cells and antibody-producing B cells for a broadly protective systemic immune response.